NRX Pharmaceuticals (NRXP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on NRX Pharmaceuticals (NRXP) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.83 of bullish evidence against -0.35 bearish.

NRX Pharmaceuticals last closed at $2.87, -1.03% on the session.

Against the IVW growth benchmark the position is -1.95% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

11 graded predictions for NRXP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks NRX Pharmaceuticals in the 97th percentile on return on equity, where 100 is best.

NRX Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $125.77M.

StockMap tracks NRX Pharmaceuticals as the 86th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite NRX Pharmaceuticals ranks 76th of 128 in the group, against a group median of -0.24.